Abstract
Background: The Alzheimers Disease Assessment Scale – Cognitive Subscale (ADAS-Cog) has become the de facto gold standard for assessing the efficacy of anti-dementia treatments. However, manual administration of the ADAS-Cog is subject to procedural inconsistencies, including scoring and transcription errors, which can introduce unwanted variance and compromise data quality within and across sites and trials. To address such concerns, a computerized version was developed that integrates, rather than replaces, the examiner, standardizes administration, and uses electronic data capture at the point of patient contact. The examiner can control administration and pacing, pause or repeat digitized instructions, score verbal report and overt behavioral performance, and freely interact with the subject. Purpose: To conduct psychometric comparisons of traditional, paper-based administration of the standard ADAS-Cog (sADAS) with examiner- assisted administration of the computerized ADAS-Cog (cADAS). Methods: Eighty-eight patients (39M; 49F) with mild to moderate Alzheimers disease were tested on three occasions with each version over a period of one year with one month between paired visits. Results: Intraclass Correlation Coefficients (ICC) comparisons between sADAS and cADAS were significant for total score (ICC=0.96) and all subscores (ICCs ranged 0.78-0.93), with no significant differences on paired t-tests. The mean ICCs across cADAS scores for test-retest reliability for short-term (mean ICC=0.96) and long-term (mean ICC=0.91) comparisons were significantly higher than across sADAS scores (mean ICCs were 0.87 and 0.84, respectively). Conclusions: These results indicate that examiner-assisted, computerized administration is equivalent to traditional, paper-based administration, and shows significantly greater test-retest reliability.
Keywords: CMINDS, cognitive assessment, computerized ADAS-Cog, concurrent validity, clinical trials, psychometric comparison, test-retest reliability, Alzheimer's Disease Assessment Scale, ideational praxis, mild cognitive impairment, ADCS, NINCDS, ADRDA, MMSE
Current Alzheimer Research
Title: Psychometric Comparison of Standard and Computerized Administration of the Alzheimers Disease Assessment Scale – Cognitive Subscale (ADASCog)
Volume: 8 Issue: 3
Author(s): J. P. O'Halloran, A. S. Kemp, D. P. Salmon, P. N. Tariot and L. S. Schneider
Affiliation:
Keywords: CMINDS, cognitive assessment, computerized ADAS-Cog, concurrent validity, clinical trials, psychometric comparison, test-retest reliability, Alzheimer's Disease Assessment Scale, ideational praxis, mild cognitive impairment, ADCS, NINCDS, ADRDA, MMSE
Abstract: Background: The Alzheimers Disease Assessment Scale – Cognitive Subscale (ADAS-Cog) has become the de facto gold standard for assessing the efficacy of anti-dementia treatments. However, manual administration of the ADAS-Cog is subject to procedural inconsistencies, including scoring and transcription errors, which can introduce unwanted variance and compromise data quality within and across sites and trials. To address such concerns, a computerized version was developed that integrates, rather than replaces, the examiner, standardizes administration, and uses electronic data capture at the point of patient contact. The examiner can control administration and pacing, pause or repeat digitized instructions, score verbal report and overt behavioral performance, and freely interact with the subject. Purpose: To conduct psychometric comparisons of traditional, paper-based administration of the standard ADAS-Cog (sADAS) with examiner- assisted administration of the computerized ADAS-Cog (cADAS). Methods: Eighty-eight patients (39M; 49F) with mild to moderate Alzheimers disease were tested on three occasions with each version over a period of one year with one month between paired visits. Results: Intraclass Correlation Coefficients (ICC) comparisons between sADAS and cADAS were significant for total score (ICC=0.96) and all subscores (ICCs ranged 0.78-0.93), with no significant differences on paired t-tests. The mean ICCs across cADAS scores for test-retest reliability for short-term (mean ICC=0.96) and long-term (mean ICC=0.91) comparisons were significantly higher than across sADAS scores (mean ICCs were 0.87 and 0.84, respectively). Conclusions: These results indicate that examiner-assisted, computerized administration is equivalent to traditional, paper-based administration, and shows significantly greater test-retest reliability.
Export Options
About this article
Cite this article as:
P. O'Halloran J., S. Kemp A., P. Salmon D., N. Tariot P. and S. Schneider L., Psychometric Comparison of Standard and Computerized Administration of the Alzheimers Disease Assessment Scale – Cognitive Subscale (ADASCog), Current Alzheimer Research 2011; 8 (3) . https://dx.doi.org/10.2174/156720511795563692
DOI https://dx.doi.org/10.2174/156720511795563692 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacotherapy of Sickle Cell Disease in Children
Current Pharmaceutical Design Editorial [Hot Topic: Exploring the Links between Obesity and Alzheimers Disease (Guest Editor: Suzana S. Petanceska) ]
Current Alzheimer Research 5-HT1 Receptors
Current Drug Targets - CNS & Neurological Disorders Anticoagulant Therapy in Very Old Patients
Cardiovascular & Hematological Disorders-Drug Targets Neuroprotective effects of the securinine-analogues: identification of Allomargaritarine as a lead compound
CNS & Neurological Disorders - Drug Targets Tyrosine Hydroxylase Gene: Another Piece of the Genetic Puzzle of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Fragile X Syndrome and Alzheimers Disease: Another Story About APP and β -Amyloid
Current Alzheimer Research Recent Insights on the Pro-Apoptotic Phenotype Elicited by Presenilin 2 and its Caspase and Presenilinase-Derived Fragments
Current Alzheimer Research Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Inhibition of Neurofibrillary Degeneration: A Promising Approach to Alzheimers Disease and Other Tauopathies
Current Drug Targets Elevated Plasma Levels of Soluble TNFRs and TACE Activity in Alzheimer's Disease Patients of Northern Han Chinese Descent
Current Alzheimer Research Bipolar Affective Disorder, Epilepsy and Migraine – Does Possible Shared Pathogenesis Explain their Association?
Current Psychopharmacology Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research Assembly, Maturation, and Trafficking of the γ-Secretase Complex in Alzheimers Disease
Current Alzheimer Research Curcumin: Structure-Activity Relationship Towards its Role as a Versatile Multi-Targeted Therapeutics
Mini-Reviews in Organic Chemistry Therapeutic Agents in Alzheimer's Disease Through a Multi-targetdirected Ligands Strategy: Recent Progress Based on Tacrine Core
Current Topics in Medicinal Chemistry Clinical Pharmacology of Novel Anti-Alzheimer Disease Modifying Medications
Current Topics in Medicinal Chemistry The Pulse of Drug Development for Alzheimers Disease
Reviews on Recent Clinical Trials A Molecular Bridge: Connecting Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Is there a Possible Single Mediator in Modulating Neuroendocrine–thymus Interaction in Ageing?
Current Aging Science